TL;DR

Isomorphic Labs, the London company founded by Sir Demis Hassabis to design medicines with AI, announced a £3.8 billion ($5 billion) Series C on 17 November. Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz joining and Alphabet investing again. The Telegraph called it the largest investment yet in a British AI start-up. The money is meant to take the company’s first drug candidates into clinical trials.

The round

The deal confirms the fundraising we reported as talks earlier this month. According to the company, every existing investor took part, among them the UK Sovereign AI Fund plus Temasek, MGX, Thrive Capital, CapitalG and GV, and the round was oversubscribed. The release does not give a valuation.

Isomorphic was founded in 2021 and is headquartered in London, with offices in Cambridge, Massachusetts and in Lausanne. Hassabis is chief executive and Max Jaderberg is president.

What the money is for

The company’s pitch rests on IsoDDE, its in-house drug design engine, which combines simulation models that work across several therapeutic areas and types of drug. Isomorphic says the engine is producing positive preclinical results in its own oncology and immunology programmes and in partnered work.

Proceeds will go on developing those models further, building a network of research partners and constructing the translational and clinical infrastructure a drug developer needs to run trials. Hassabis said the round would help drive “our first therapeutic programs towards clinical trials”.

That framing matters. Despite the headline sums, Isomorphic has not yet put a medicine into human testing, so its results so far are preclinical claims from the company rather than trial data.

Looking forward

For UK readers, the UK Sovereign AI Fund’s place on the cap table, alongside US venture money, is the policy thread. In our view, this round is less a test of AI drug design than of patience: investors are funding the years between a promising molecule and a licensed medicine. The milestone to watch is the first Isomorphic-designed candidate entering a clinical trial, which the company has not dated.